What is HC Wainwright's Forecast for Metagenomi Q2 Earnings?

Metagenomi, Inc. (NASDAQ:MGX - Free Report) - Investment analysts at HC Wainwright decreased their Q2 2025 earnings per share (EPS) estimates for Metagenomi in a report released on Tuesday, May 27th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings per share of ($0.54) for the quarter, down from their prior forecast of ($0.51). HC Wainwright currently has a "Buy" rating and a $7.00 target price on the stock. The consensus estimate for Metagenomi's current full-year earnings is ($2.46) per share. HC Wainwright also issued estimates for Metagenomi's Q3 2025 earnings at ($0.57) EPS, Q4 2025 earnings at ($0.62) EPS, FY2025 earnings at ($2.41) EPS and FY2026 earnings at ($2.91) EPS.

Metagenomi (NASDAQ:MGX - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.68) EPS for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.06). Metagenomi had a negative return on equity of 43.23% and a negative net margin of 134.27%. The company had revenue of $4.13 million during the quarter, compared to the consensus estimate of $8.75 million.

Several other analysts have also recently issued reports on MGX. Wells Fargo & Company reiterated an "overweight" rating and issued a $16.00 target price (down from $20.00) on shares of Metagenomi in a research note on Wednesday, May 14th. Chardan Capital dropped their price objective on Metagenomi from $13.00 to $12.00 and set a "buy" rating for the company in a research note on Thursday, May 15th. Finally, Wall Street Zen lowered Metagenomi from a "hold" rating to a "strong sell" rating in a research note on Thursday, May 22nd. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. According to data from MarketBeat, Metagenomi has an average rating of "Moderate Buy" and a consensus target price of $13.00.

Metagenomi Stock Performance

NASDAQ MGX traded up $0.11 on Thursday, hitting $1.81. The stock had a trading volume of 229,405 shares, compared to its average volume of 791,607. Metagenomi has a 52-week low of $1.23 and a 52-week high of $6.90. The company has a market capitalization of $67.81 million, a price-to-earnings ratio of -0.86 and a beta of -0.65. The firm has a 50-day moving average of $1.56 and a 200-day moving average of $2.24.

Institutional Investors Weigh In On Metagenomi

Hedge funds have recently added to or reduced their stakes in the company. Voya Investment Management LLC bought a new stake in Metagenomi during the fourth quarter worth about $37,000. Price T Rowe Associates Inc. MD purchased a new position in Metagenomi in the 4th quarter worth $39,000. Rhumbline Advisers raised its position in Metagenomi by 123.3% in the 4th quarter. Rhumbline Advisers now owns 11,998 shares of the company's stock worth $43,000 after purchasing an additional 6,626 shares during the period. SG Americas Securities LLC purchased a new position in Metagenomi in the 4th quarter worth $43,000. Finally, Corebridge Financial Inc. raised its position in Metagenomi by 303.1% in the 4th quarter. Corebridge Financial Inc. now owns 13,602 shares of the company's stock worth $49,000 after purchasing an additional 10,228 shares during the period.

Metagenomi Company Profile

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.